These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
169 related items for PubMed ID: 19617818
1. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study. Benesch M, Siegler N, Hoff Kv, Lassay L, Kropshofer G, Müller H, Sommer C, Rutkowski S, Fleischhack G, Urban C. Anticancer Drugs; 2009 Oct; 20(9):794-9. PubMed ID: 19617818 [Abstract] [Full Text] [Related]
2. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis. Benesch M, Sovinz P, Krammer B, Lackner H, Mann G, Schwinger W, Gadner H, Urban C. J Pediatr Hematol Oncol; 2007 Apr; 29(4):222-6. PubMed ID: 17414563 [Abstract] [Full Text] [Related]
4. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia. Sommer C, Lackner H, Benesch M, Sovinz P, Schwinger W, Moser A, Bergloeff J, Gruber A, Urban C. Ann Hematol; 2008 Nov; 87(11):887-90. PubMed ID: 18575860 [Abstract] [Full Text] [Related]
5. Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years. Peyrl A, Sauermann R, Traunmueller F, Azizi AA, Gruber-Olipitz M, Gupper A, Slavc I. Clin Pharmacokinet; 2009 Nov; 48(4):265-71. PubMed ID: 19492871 [Abstract] [Full Text] [Related]
6. Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation. Hilgendorf I, Wolff D, Junghanss C, Kahl C, Leithaeuser M, Steiner B, Casper J, Freund M. Ann Hematol; 2008 Dec; 87(12):1009-12. PubMed ID: 18704421 [Abstract] [Full Text] [Related]
7. Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases. Sancho JM, Ribera JM, Romero MJ, Martín-Reina V, Giraldo P, Ruiz E. Haematologica; 2006 Mar; 91(3):ECR02. PubMed ID: 16533729 [Abstract] [Full Text] [Related]
8. Intrathecal liposomal cytarabine in relapsed or refractory infant and pediatric leukemias: the Children's Hospital of Philadelphia experience and review of the literature. Seif AE, Reilly AF, Rheingold SR. J Pediatr Hematol Oncol; 2010 Nov; 32(8):e349-52. PubMed ID: 20962675 [Abstract] [Full Text] [Related]
11. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, O'Day SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L, Howell SB. Br J Cancer; 2001 Jan; 84(2):157-63. PubMed ID: 11161370 [Abstract] [Full Text] [Related]
12. Safety and tolerability of intrathecal liposomal cytarabine as central nervous system prophylaxis in patients with acute lymphoblastic leukemia. Valentin A, Troppan K, Pfeilstöcker M, Nösslinger T, Linkesch W, Neumeister P. Leuk Lymphoma; 2014 Aug; 55(8):1739-42. PubMed ID: 24138308 [Abstract] [Full Text] [Related]
13. Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma. Spina M, Chimienti E, Martellotta F, Vaccher E, Berretta M, Zanet E, Lleshi A, Canzonieri V, Bulian P, Tirelli U. Cancer; 2010 Mar 15; 116(6):1495-501. PubMed ID: 20108270 [Abstract] [Full Text] [Related]
14. Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Garcia-Marco JA, Panizo C, Garcia ES, Deben G, Alvarez-Larran A, Barca EG, Sancho JM, Penarrubia MJ, Garcia-Cerecedo T, Garcia Vela JA. Cancer; 2009 May 01; 115(9):1892-8. PubMed ID: 19235254 [Abstract] [Full Text] [Related]
15. Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers. Jurczak W, Kroll-Balcerzak R, Giebel S, Machaczka M, Giza A, Ogórka T, Fornagiel S, Rybka J, Wróbel T, Kumiega B, Skotnicki AB, Komarnicki M. Med Oncol; 2015 Apr 01; 32(4):90. PubMed ID: 25716885 [Abstract] [Full Text] [Related]
16. [Liposomal cytarabine in prophylaxis of the central nervous system involvement in rare aggresive lymphomas]. Kumiega B, Jurczak W, Fornagiel S, Dzietczenia J, Skotnicki AB. Przegl Lek; 2013 Apr 01; 70(4):187-90. PubMed ID: 23991555 [Abstract] [Full Text] [Related]
18. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF, Howell SB. Clin Cancer Res; 1999 Nov 01; 5(11):3394-402. PubMed ID: 10589750 [Abstract] [Full Text] [Related]
19. Pharmacokinetics and toxicity of intrathecal liposomal cytarabine in children and adolescents following age-adapted dosing. Peyrl A, Sauermann R, Chocholous M, Azizi AA, Jäger W, Höferl M, Slavc I. Clin Pharmacokinet; 2014 Feb 01; 53(2):165-73. PubMed ID: 24129691 [Abstract] [Full Text] [Related]